PRIMARY OBJECTIVES:~I. Feasibility. II. Acceptability. III. Capecitabine/Xeloda adherence.~EXPLORATORY OBJECTIVES:~I. Symptom burden. II. Patent physician communication. III. Quality of life. IV. Self-efficacy for managing symptoms.~OUTLINE: Patients are randomized to 1 of 2 groups.~GROUP I: Patients receive a SMRxT smart pill bottle, report symptoms weekly, and receive reminders for missing or incorrect dose for standard of care 3-week capecitabine/Xeloda treatment cycles.~GROUP II: Patients receive standard of care.~After completion of study, patients are followed up for 90 days after the initiation of capecitabine/Xeloda.
This clinical trial evaluates the feasibility and acceptability of a mobile health device in improving oral chemotherapy adherence in women with triple negative breast cancer that has not spread to other places in the body (non-metastatic). A mobile health device, called SMRxT smart pill bottle may help doctors to remind patients to take medicine on time and monitor their symptoms.